InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $2.440 0.22 (9.91%)+
Announcement
Release
30 Apr 2026 9:56AM
Price at Release
$2.220
Full Release
download
Summary
Mesoblast Limited reported a strong financial and operational quarter for the period ending March 31, 2026. The company's product, Ryoncil®, achieved net revenues of US$30.3 million, contributing to nearly US$100 million in revenue since its launch. Mesoblast improved its net operating cash spend to US$4.1 million, driven by significant receipts of US$34.6 million and strict control of expenses. The company ended the quarter with US$122 million in cash. Operationally, Mesoblast completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. The company also highlighted advancements in their therapeutic portfolio, including FDA clearance for a trial in Duchenne’s muscular dystrophy and the acquisition of a chimeric antigen receptor technology platform for enhanced cell therapy products.
Key Points
  • Ryoncil® net revenues reached US$30.3 million for the quarter.
  • Total cash at the quarter's end was US$122 million.
  • Net operating cash spend improved to US$4.1 million.
  • Achieved patient recruitment target for chronic low back pain trial.
  • FDA cleared Mesoblast's trial for Duchenne’s muscular dystrophy.
  • Acquired CAR technology for enhanced cell therapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.